2185.HK

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$2.2B	+104.0%	$-0.22	$-0.22–$-0.22	—	1
2027	$408M	-81.2%	$-0.12	$-0.12–$-0.12	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$5.21

Price

$1.65

Implied upside

+216%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
2185.HKShanghai Bio-heart Biological Technology Co., Ltd.	$1.66	+3.43%	$391M	—
1244.HK3D Medicines Inc.	$2.32	-1.69%	$571M	—
1521.HKFrontage Holdings Corporation	$1.10	+0.00%	$2.2B	—
2126.HKJW (Cayman) Therapeutics Co. Ltd	$2.04	+2.01%	$848M	—
2181.HKMabpharm Limited	$0.42	-3.45%	$1.7B	—
2487.HKCutia Therapeutics	$1.43	+4.76%

Source: Financial Modeling Prep · peers by sector/industry

Shanghai Bio-heart Biological Technology Co., Ltd.

Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.

www.bio-heart.com

Employees: 63
IPO / List date: Dec 23, 2021
HQ: CN

Held by traders on TradeandTell

No one on the platform currently holds 2185.HK.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 2185.HK as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 2185.HK yet.